Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring
17 févr. 2021 08h30 HE
|
Ehave
Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar...
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
10 févr. 2021 08h00 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Inotiv Broadens Pathology Service Offerings
19 janv. 2021 08h33 HE
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of...
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
07 janv. 2021 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
11 déc. 2020 11h21 HE
|
Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
27 août 2020 07h59 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
25 août 2020 23h00 HE
|
Fluidigm Corporation
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent...
Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
06 juil. 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...